Investors Urged to Take Action in Soleno Therapeutics Securities Fraud Case

Take Action: Join the Soleno Therapeutics Class Action

Investors in Soleno Therapeutics, Inc. are being reminded of a crucial opportunity to become involved in a securities fraud lawsuit led by the Rosen Law Firm, a recognized name in investor rights. For individuals who purchased common stock of Soleno Therapeutics, Inc. (NASDAQ: SLNO) between March 26, 2025, and November 4, 2025, an important lead plaintiff deadline is fast approaching on May 5, 2026.

Why This Matters

Purchasers within the defined Class Period may have the chance to receive compensation without incurring any out-of-pocket expenses, courtesy of a contingency fee agreement. This is a vital moment for investors who believe they were misled or experienced losses due to alleged fraudulent activities related to the company’s disclosures and communications.

What Investors Should Do Next

Those interested in joining the class action lawsuit should visit Rosen Legal for additional information or reach out to attorney Phillip Kim at 866-767-3653 or via email at [email protected]. Interested parties must act before the May 5 deadline to ensure consideration as lead plaintiffs, who will guide the litigation on behalf of the other class members.

The Importance of Selecting the Right Counsel

Rosen Law Firm emphasizes the necessity for investors to choose experienced legal representation with a proven track record in significant legal battles, particularly securities class actions. Many firms simply act as referral services, lacking the necessary skills and resources to effectively litigate complex cases. With a solid history of success, including notable settlements and recognitions, the Rosen Law Firm stands out as an advocate for investors' rights.

Details of the Case

The class action lawsuit alleges that Soleno Therapeutics made numerous false or misleading statements and failed to disclose significant safety concerns regarding their product, DCCR (diazoxide choline extended-release tablets), used for treating hyperphagia in individuals with Prader-Willi syndrome. They allegedly downplayed evidence of serious safety issues, including risks of excess fluid retention in trial participants. The lawsuit claims that these omissions materially impacted the product's commercial viability, exposing investors to unforeseen risks once the truth was revealed.

The Financial Impact

Upon receipt of accurate information about DCCR's safety and associated risks, investors reportedly incurred notable financial damages. To keep up with future updates, investors can follow the Rosen Law Firm on LinkedIn, Twitter, or Facebook.

Next Steps for Interested Investors

It is critical to act promptly as no class has been certified yet. Individuals who do not wish to be part of this class action can still choose to remain uninvolved or select their own legal counsel. The potential for recovery in future proceedings does not rest on being a lead plaintiff, allowing flexibility in how investors can approach the situation.

In conclusion, the Rosen Law Firm encourages affected investors to take timely action in asserting their rights and seeking the compensation they deserve. With expert legal counsel and a solid reputation, they aim to provide unwavering support throughout this complex legal landscape.